EconPapers    
Economics at your fingertips  
 

Standardization for innovation: The adoption of drug entity identification in the pharmaceutical industry for public health

Li-Min Chuang, Wei-Jen Chen and Min-Tsai Lai

Advances in Management and Applied Economics, 2019, vol. 9, issue 4, 4

Abstract: Whether the pharmaceutical factory has already performed in-plant drug entity identification, whether the newly-developed drug product has implemented drug entity identification, the government aspect of company cooperation with the Department of Health to subsidize pharmaceutical factories to implement drug entity identification, the government aspect of the Department of Health arranging project grants to encourage the pharmaceutical factories to implement drug entity identification, the government aspect of the government’s need to mandate regulations for drug entity identification, the government aspect of the government’s need to continue to provide subsidies to pharmaceutical factories to implement drug entity identification, the implementation aspect of drugs should implement entity identification, the implementation aspect of company belief that the implementation of drug entity identification is most needed by the public, the implementation aspect of company belief that the implementation of drug entity identification is most needed by medical institutions, the benefit aspect of company belief that the implementation of drug entity identification is most beneficial to medical institutions, and the cost aspect of company belief that the implementation of drug entity identification will increase the manufacturing costs of the pharmaceutical factories, have a significant impact on the willingness to cooperate. The site of the pharmaceutical factory had a significant impact on drug identification implementation, as shown by the Chi-square test. In addition, the proportion of domestic sales of pharmaceutical plants and the number of Western drug items had a significant impact on the ratio of drug entity identification, as found by the chi-square test.JEL classification numbers: C83, M15, O31Keywords: Standardization, Innovation, Drug Entity Identification, Public Health

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed

Downloads: (external link)
http://www.scienpress.com/Upload/AMAE%2fVol%209_4_4.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spt:admaec:v:9:y:2019:i:4:f:9_4_4

Access Statistics for this article

More articles in Advances in Management and Applied Economics from SCIENPRESS Ltd
Bibliographic data for series maintained by Eleftherios Spyromitros-Xioufis ().

 
Page updated 2019-04-27
Handle: RePEc:spt:admaec:v:9:y:2019:i:4:f:9_4_4